Alnylam Pharmaceuticals (LTS:0HD2) Beneish M-Score: -1.74 (As of Jun. 25, 2026)


LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
67 GF Score
Price $298.72
GF Value $521.88
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals Beneish M-Score?

Alnylam Pharmaceuticals LTS:0HD2 +3.06% 67 Beneish M-Score is -1.74 as of Jun. 25, 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $521.88 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Alnylam Pharmaceuticals ranks worse than 67.87% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.74 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Alnylam Pharmaceuticals's Beneish M-Score or its related term are showing as below:

LTS:0HD2' s Beneish M-Score Range Over the Past 10 Years
Min: -3.91   Med: -2.25   Max: 4.92
Current: -1.74

During the past 13 years, the highest Beneish M-Score of Alnylam Pharmaceuticals was 4.92. The lowest was -3.91. And the median was -2.25.


Alnylam Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Beneish M-Score Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.90 -2.72 -2.47 -2.04 -1.96

Alnylam Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.92 -1.69 -1.22 -1.96 -1.74

LTS:0HD2 vs RVMD, ONC, RPRX: Beneish M-Score Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Beneish M-Score falls into.


LTS:0HD2
67GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Alnylam Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1582+0.528 * 1.0642+0.404 * 0.667+0.892 * 1.8257+0.115 * 1.0626
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7051+4.679 * -0.028426-0.327 * 0.908
=-1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $884 Mil.
Revenue was 1167.175 + 1097.033 + 1249.026 + 773.689 = $4,287 Mil.
Gross Profit was 956.053 + 829.31 + 1048.872 + 630.736 = $3,465 Mil.
Total Current Assets was $4,219 Mil.
Total Assets was $5,130 Mil.
Property, Plant and Equipment(Net PPE) was $708 Mil.
Depreciation, Depletion and Amortization(DDA) was $55 Mil.
Selling, General, & Admin. Expense(SGA) was $1,293 Mil.
Total Current Liabilities was $1,349 Mil.
Long-Term Debt & Capital Lease Obligation was $1,227 Mil.
Net Income was 205.991 + 186.419 + 251.084 + -66.277 = $577 Mil.
Non Operating Income was -4.295 + 132.126 + -113.296 + -6.399 = $8 Mil.
Cash Flow from Operations was 70.504 + 163.555 + 325.109 + 155.728 = $715 Mil.
Total Receivables was $418 Mil.
Revenue was 594.189 + 593.166 + 500.919 + 659.825 = $2,348 Mil.
Gross Profit was 523.148 + 490.349 + 415.014 + 591.153 = $2,020 Mil.
Total Current Assets was $3,268 Mil.
Total Assets was $4,214 Mil.
Property, Plant and Equipment(Net PPE) was $696 Mil.
Depreciation, Depletion and Amortization(DDA) was $58 Mil.
Selling, General, & Admin. Expense(SGA) was $1,005 Mil.
Total Current Liabilities was $1,076 Mil.
Long-Term Debt & Capital Lease Obligation was $1,256 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(883.957 / 4286.923) / (418.035 / 2348.099)
=0.206198 / 0.178031
=1.1582

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2019.664 / 2348.099) / (3464.971 / 4286.923)
=0.860127 / 0.808265
=1.0642

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4219.308 + 707.556) / 5129.547) / (1 - (3268.258 + 695.917) / 4213.811)
=0.039513 / 0.059242
=0.667

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4286.923 / 2348.099
=1.8257

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(57.558 / (57.558 + 695.917)) / (54.806 / (54.806 + 707.556))
=0.07639 / 0.07189
=1.0626

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1293.315 / 4286.923) / (1004.678 / 2348.099)
=0.301688 / 0.427869
=0.7051

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1227.397 + 1349.475) / 5129.547) / ((1255.627 + 1075.623) / 4213.811)
=0.502359 / 0.55324
=0.908

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(577.217 - 8.136 - 714.896) / 5129.547
=-0.028426

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Alnylam Pharmaceuticals has a M-score of -1.74 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.74 mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Beneish M-Score of -1.74 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alnylam Pharmaceuticals and its competitors. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #564 out of 831 companies in the Biotechnology industry, placing it in the top 67.9%.
Is Alnylam Pharmaceuticals' Beneish M-Score too high?
Alnylam Pharmaceuticals' current Beneish M-Score is -1.74. Based on the distribution chart, Alnylam Pharmaceuticals ranks #564 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Beneish M-Score compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #564 out of 831 companies for Beneish M-Score. This places Alnylam Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Beneish M-Score is -1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $521.88, compared to a current price of $298.72 — trading 42.8% below its estimated fair value. The current Beneish M-Score is -1.74. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Beneish M-Score is -1.74 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $298.72 is trading 42.8% below its estimated GF Value™ of $521.88. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Beneish M-Score: -1.74
  • GF Value™: $521.88 vs. price of $298.72 (42.8% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score

Get the complete analysis for LTS:0HD2

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$298.72
Price
$521.88
GF Value